Healthcare
Executive compensation benchmarks for 35 public companies in the pharmaceutical preparations industry.
$10.4M
35
$32.5M
5:1
Median
$10,364,688
Average
$11,740,936
25th Percentile
$8,012,502
75th Percentile
$15,085,576
Minimum
$937,500
Maximum
$32,530,984
Avg Pay Ratio
5:1
Companies
35
Published peer groups
Compare the company-size groups with enough data to support a distinct benchmark.
Click any company to see full compensation breakdown
The median pharmaceutical preparations CEO compensation is $10,364,688, based on 35 public companies. The average is $11,740,936. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Robert A. Michael of AbbVie Inc. is the highest paid pharmaceutical preparations CEO, with total compensation of $32,530,984 in FY2025.
The average CEO-to-median-employee pay ratio in the pharmaceutical preparations industry is 5:1. This means the average CEO earns 5 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: October 14, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| AbbVie Inc. ABBV | Robert A. Michael | $32.5M |
| Roivant Sciences Ltd. ROIV | Eric Venker | $24.4M |
| ABBOTT LABORATORIES ABT | Robert B. Ford | $24.2M |
| MADRIGAL PHARMACEUTICALS, INC. MDGL | Bill Sibold | $19.2M |
| UNITED THERAPEUTICS Corp UTHR | Martine Rothblatt | $18.0M |
| Nuvalent, Inc. NUVL | James R. Porter | $17.3M |
| Organon & Co. OGN | Kevin Ali | $15.8M |
| SUPERNUS PHARMACEUTICALS, INC. SUPN | Jack A. Khattar | $15.5M |
| CORCEPT THERAPEUTICS INC CORT | Joseph K. Belanoff | $15.3M |
| Alnylam Pharmaceuticals, Inc. ALNY | Yvonne L. Greenstreet | $14.9M |
| RHYTHM PHARMACEUTICALS, INC. RYTM | David P. Meeker | $14.7M |
| INSMED Inc INSM | William H. Lewis | $14.5M |
| Atrium Therapeutics, Inc. RNA | Sarah Boyce | $14.2M |
| Apellis Pharmaceuticals, Inc. APLS | Cedric Francois | $13.3M |
| Protagonist Therapeutics, Inc PTGX | Dinesh V. Patel | $12.9M |
| Pacira BioSciences, Inc. PCRX | Frank Lee | $11.6M |
| Sanofi SNY | Paul Hudson | $10.8M |
| Axsome Therapeutics, Inc. AXSM | Herriot Tabuteau | $10.4M |
| Merus N.V. MRUS | Sven (Bill) Ante Lundberg | $9.7M |
| Arcus Biosciences, Inc. RCUS | Terry Rosen | $9.7M |
| VERTEX PHARMACEUTICALS INC / MA VRTX | Reshma Kewalramani | $9.1M |
| PERRIGO Co plc PRGO | Patrick Lockwood-Taylor | $9.0M |
| ARROWHEAD PHARMACEUTICALS, INC. ARWR | Christopher Anzalone | $9.0M |
| Amneal Pharmaceuticals, Inc. AMRX | Chintu Patel | $8.7M |
| ACADIA PHARMACEUTICALS INC ACAD | Catherine Owen | $8.3M |
| REGENERON PHARMACEUTICALS, INC. REGN | Leonard S. Schleifer | $8.2M |
| Sarepta Therapeutics, Inc. SRPT | Douglas S. Ingram | $7.8M |
| PTC THERAPEUTICS, INC. PTCT | Matthew B. Klein | $7.4M |
| Xencor Inc XNCR | Bassil I. Dahiyat | $5.5M |
| PHIBRO ANIMAL HEALTH CORP PAHC | Jack C. Bendheim | $4.8M |
| Schrodinger, Inc. SDGR | Ramy Farid | $4.1M |
| Grifols SA GRFS | José Ignacio (Nacho) Abia Buenache | $3.8M |
| ANI PHARMACEUTICALS INC ANIP | Nikhil Lalwani | $3.7M |
| COLLEGIUM PHARMACEUTICAL, INC COLL | Vikram Karnani | $1.7M |
| Royalty Pharma plc RPRX | Pablo Legorreta | $938K |